Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BioSyent to Present at Upcoming Investor Conference

TORONTO, Aug. 24, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture: RX) is pleased to announce that it will be presenting at the Midwest IDEAS Investor Conference at The Gwen in Chicago, Illinois. Mr.  René  Goehrum, BioSyent’s President  and  CEO, will present  to  investors  an overview  of  BioSyent’s business and  corporate  activities on Wednesday, August 29th at 9:20 a.m. ET. Mr. Goehrum will also be available for one-on-one meetings during the day on August 29th.  Interested investors can request meetings with Mr. Goehrum through the online conference platform: https://www.meetmax.com/sched/event_48313/entity_login.html?attendee_role_id=COMPANY

  
About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.  

As of the date of this press release, the Company has 14,519,603 common shares issued and outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013
E-Mail: [email protected]
Web: www.biosyent.com

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).